Syngensys

Syngensys is a private, pre-revenue biotech company applying synthetic biology and machine learning to solve critical gene expression challenges in advanced therapies and industrial bioproduction. Its core offering is the 'Sypher' platform, which uses deep learning on transcriptional data to design novel synthetic promoters and other genetic components for specific therapeutic or manufacturing applications. The company operates a hybrid business model, offering both off-the-shelf promoter products for areas like liver, muscle, and NK cell therapies, as well as custom design and development services for biopharma partners. Headquartered in Cambridge, UK, with an operational office in Sheffield, Syngensys is positioned at the intersection of AI-driven drug discovery and the rapidly growing cell & gene therapy market.

Sypher - An integrated AI/ML-driven platform for transcriptional analysis and synthetic genetic component design. It uses deep learning on genomic data to computationally design, test, and validate novel gene promoters and other genetic parts for specific applications in biomanufacturing and cell & gene therapy.

Syngensys competes in the synthetic biology tools space for biopharma. Competitors range from large reagent/tool providers (e.g., Thermo Fisher, Merck KGaA) with broad genetic part portfolios to specialized startups focusing on gene regulation or cell therapy engineering. Differentiation hinges on the predictive power and output quality of its proprietary Sypher AI/ML platform compared to more empirical design methods.